NCT05972993 - A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

May 9, 2024

Study Completion Date

October 14, 2024

Conditions

COVID-19

Interventions

BIOLOGICAL

mRNA-CR-04 vaccine 10μg

mRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

BIOLOGICAL

mRNA-CR-04 vaccine 30μg

mRNA CR-04 vaccine, 30 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

BIOLOGICAL

mRNA-CR-04 vaccine 100μg

mRNA CR-04 vaccine, 100 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

DRUG

Placebo

Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

BIOLOGICAL

mRNA-CR-04 vaccine 3μg

mRNA CR-04 vaccine, 3 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

Trial Locations (4)

GSK Investigational Site, Melbourne

GSK Investigational Site, Peoria

GSK Investigational Site, Austin

GSK Investigational Site, San Diego